Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.

Kawano H, Suzuki T, Ishii S, Wakahashi K, Kawano Y, Sada A, Minagawa K, Ueno D, Yamasaki T, Itoh T, Yokozaki H, Katayama Y.

Eur J Haematol. 2014 Apr;92(4):362-4. doi: 10.1111/ejh.12249. Epub 2014 Jan 10. No abstract available.

PMID:
24341928
2.

Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.

Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, Verma A.

Am J Hematol. 2009 Oct;84(10):688-9. doi: 10.1002/ajh.21510. No abstract available.

3.

Azacitidine-associated Sweet's syndrome.

Trickett HB, Cumpston A, Craig M.

Am J Health Syst Pharm. 2012 May 15;69(10):869-71. doi: 10.2146/ajhp110523.

PMID:
22555082
4.

Azacitidine: a new medication associated with Sweet syndrome.

Tintle S, Patel V, Ruskin A, Halasz C.

J Am Acad Dermatol. 2011 May;64(5):e77-9. doi: 10.1016/j.jaad.2010.06.032. No abstract available.

PMID:
21496689
5.

[Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].

Mishima M, Makita M, Sando Y, Yamamoto Y, Shiote Y, Hara Y, Yamamoto K, Imajo K.

Rinsho Ketsueki. 2015 Jan;56(1):35-7. doi: 10.11406/rinketsu.56.35. Japanese.

PMID:
25745966
6.

Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome.

Lin CH, Yeh SP, Lin TY.

Ann Hematol. 2015 Nov;94(11):1925-6. doi: 10.1007/s00277-015-2458-0. Epub 2015 Aug 2. No abstract available.

PMID:
26233682
7.

Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.

Martinelli S, Rigolin GM, Leo G, Gafà R, Lista E, Cibien F, Sofritti O, Daghia G, Cavazzini F, Cuneo A.

Int J Hematol. 2014;99(5):663-7. doi: 10.1007/s12185-014-1527-9. Epub 2014 Feb 20.

PMID:
24554168
8.

Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.

Park JY, Park JS, Kim YC.

Eur J Dermatol. 2012 Nov-Dec;22(6):811-2. doi: 10.1684/ejd.2012.1861. No abstract available.

PMID:
23178879
9.

Histiocytoid Sweet syndrome and cutaneous polyarteritis nodosa secondary to myelodysplastic syndrome.

Pinal-Fernandez I, Ferrer Fabrega B, Ramentol Sintas M, Solans Laque R.

Int J Rheum Dis. 2013 Dec;16(6):777-9. doi: 10.1111/1756-185X.12103. Epub 2013 Jun 3. No abstract available.

PMID:
24382288
10.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

11.

Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.

Ichikawa K, Aritaka N, Ogura K, Komatsu N, Hirano T.

Geriatr Gerontol Int. 2014 Oct;14(4):1006-7. doi: 10.1111/ggi.12226. No abstract available.

PMID:
25327907
12.

Is there an association between 5-azacitidine and ototoxicity?

Malik A, Misbah S, Spaccavento C, Yudelman I.

J Clin Pharmacol. 2010 Sep;50(9):1056-7. doi: 10.1177/0091270009360536. Epub 2010 Mar 16. No abstract available.

PMID:
20234015
13.

Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.

Adams CD, Szumita PM, Baroletti SA, Lilly CM.

Pharmacotherapy. 2005 May;25(5):765-8.

PMID:
15899739
14.

Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.

Hayashi M, Takayasu H, Tada M, Yamazaki Y, Tateno H, Tazawa S, Wakabayashi A, Iwasaki T, Tsuchiya Y, Yamashita J, Takeda N, Tomita S, Mori H, Kokubu F.

Intern Med. 2012;51(17):2411-5. Epub 2012 Sep 1. Review.

15.

Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.

Stamatoullas A, Rezine I, Mareschal S, Ménard AL, Lanic H, David M, Daliphard S, Penther D, Lemasle E, Cassuto O, Lenain P, Contentin N, Lepretre S, Jardin F, Bastard C, Tilly H.

Leuk Lymphoma. 2016;57(6):1491-3. doi: 10.3109/10428194.2015.1101096. Epub 2015 Nov 16. No abstract available.

PMID:
26430832
16.

Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.

Kim IH, Youn JH, Shin SH, Yahng SA, Lee SE, Kwon JC, Lee DG, Park KS, Choi MH, Jung SE, Kim YJ.

Leuk Res. 2012 Jul;36(7):e146-8. doi: 10.1016/j.leukres.2012.03.007. Epub 2012 Apr 5. No abstract available.

PMID:
22483068
17.

Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.

D'Alò F, Leone G, Hohaus S, Teofili L, Bozzoli V, Tisi MC, Rufini V, Calcagni ML, Voso MT.

Br J Haematol. 2011 Jul;154(1):141-3. doi: 10.1111/j.1365-2141.2010.08438.x. Epub 2011 Feb 20. No abstract available.

PMID:
21332703
18.

Azacitidine and the beginnings of therapeutic epigenetic modulation.

O'Dwyer K, Maslak P.

Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981 . Review.

PMID:
18627335
19.

Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.

Feldmann G, Brossart P, von Lilienfeld-Toal M.

Ann Hematol. 2013 Nov;92(11):1577-9. doi: 10.1007/s00277-013-1748-7. Epub 2013 Apr 13. No abstract available.

PMID:
23584506
20.

Interstitial lung disease associated with azacitidine use: a case report.

Sekhri A, Palaniswamy C, Kurmayagari K, Kalra A, Selvaraj DR.

Am J Ther. 2012 Mar;19(2):e98-e100. doi: 10.1097/MJT.0b013e3181e7a526.

PMID:
20634671

Supplemental Content

Support Center